BioSpace News Archive

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Carina Freedman, who joined the Company as Clinical Trial Manager.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), today announced that it has been granted United States Patent No. 11,185,523, “Use of Bipolar Trans Carotenoids With Chemotherapy and Radiotherapy for Treatment of Cancer,” by the United States Patent and Trademark Office.

SAB Biotherapeutics today announced that SAB-176, its investigational therapeutic for the treatment of seasonal influenza, achieved statistically significant (p = 0.026) reductions in viral load and clinical signs and symptoms

Samus Therapeutics, Inc. (“Samus Therapeutics” or the “Company”), today announced the publication on November 25, 2021 of an open article in Communications Biology about how epichaperome inhibition by zelavespib (PU-H71) can increase the vulnerability of cancer cells to traditionally poor performing therapeutics.

Parthenon Therapeutics today announced the appointment of Tamas Oravecz, Ph.D., as Chief Scientific Officer.

Genesis Innovation Group’s cultivate(MD) Capital Funds announces that one of their portfolio companies, Virtual Incision Corporation, a medical device company pioneering first-of-its-kind miniaturized robots for laparoscopic surgery, has raised $46 million in a Series C funding round.

Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the annual American Society of Hematology (ASH) meeting.

Paragon 28, Inc. announced today the appointment of B. Kristine Johnson and Kristina Wright to the Board of Directors, effective December 1, 2021.

Gelesis, a consumer-focused biotherapeutics company, is proud to announce Plenity®, an FDA cleared weight management approach, is now broadly available across the United States to adults who meet the prescription criteria.

2seventy bio, Inc . (Nasdaq: TSVT), an emerging immuno-oncology company, today reported financial results and recent highlights for the third quarter ended September 30, 2021.